-
Who we are
Who we are
Novavax is a global biotechnology company with a proven vaccine technology. We are focused on developing our R&D assets and establishing partnerships to leverage the value of our technology to help protect health.
Discover our scienceLearn about our validated protein-based nanoparticle and Matrix-M™ adjuvant technology.
-
What we do
What we do
Novavax is focused on using our proven vaccine technology to help protect health through the development of our R&D assets and establishing partnerships
Latest UpdatesStay current with Novavax news as we make progress in discovering and developing innovative vaccines to help protect against serious infectious diseases.
-
Blog
Blog
Novavax is committed to accelerating the development of new and promising vaccines and sharing information based on years of study and experience.
Pipeline
Our R&D strategy leverages our validated technology platform with a focus on expanding beyond our existing core expertise in COVID-19, influenza, and COVID-19-Influenza Combination (CIC) vaccines.
We are identifying early-stage pipeline and innovation expansion opportunities to support long-term growth. Early work will include strategically moving forward with RSV and pandemic flu, which are disease areas that leverage our existing experience and internal expertise in infectious diseases. Our next step is to identify other infectious disease areas that are or could become vaccine-preventable, meet other guiding principles, and for which our technology could possess differentiating attributes. Finally, we will potentially expand more broadly beyond infectious diseases, by leveraging specialized scientific knowledge and robust translational models to evaluate a range of chronic diseases where our technology could lead to the development of preclinical constructs to advance to proof of mechanism and proof of concept studies, and beyond.
Our pipeline
Novavax aims to develop innovative vaccines that may help improve lives and fight infectious diseases around the world. The table below lists our selected research and development priorities.
Our Matrix-M adjuvant technology
The vaccines listed below with the Matrix-M symbol have been developed with the Matrix-M adjuvant.
Therapeutic area | Candidate | Phase of trial | Authorized Use | Partner | |||
---|---|---|---|---|---|---|---|
Preclinical | Phase 1 | Phase 2 | Phase 3 | ||||
Respiratory diseases COVID-19 | Novavax COVID-19 vaccine | Authorized1 | |||||
Respiratory diseases COVID-19 + seasonal influenza | COVID-influenza combination (CIC) vaccine | Phase 3 | Novavax led | ||||
Respiratory diseases Seasonal influenza | Influenza vaccine (Older Adults) | Phase 3 | Novavax led | ||||
Respiratory diseases Respiratory syncytial virus (RSV) | RSV Combinations | Preclinical | Novavax led | ||||
Respiratory diseases Pandemic Influenza | Influenza | Preclinical | Novavax led | ||||
Developed by partners leveraging Novavax technology | |||||||
Parasitic diseases Malaria | R21/Matrix-MTM adjuvant | Authorized2 |
1 Authorized in select geographies under trade names Novavax COVID-19 Vaccine, Adjuvanted; Covovax™; and Nuvaxovid™. Authorization information can be found by country at https://novavaxcovidvaccine.com.
2 Commercialized by Serum Institute of India and granted prequalification by the WHO and distributed by UNICEF to endemic countries in Africa.